mergers and acquisition

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

The scientific supply giant seeks to expand into biopharma development and manufacturing.  

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

The US agribusiness behemoth agreed to a $57 billion buyout offer from the European pharmaceutical giant.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

American Society of Clinical Oncology meeting edition 

In a $4.2 billion deal, the science equipment giant is buying the Hillsboro, Oregon-based electron microscope maker.

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.

Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.

In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.

The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.